ClinicalTrials.gg
RecruitingNCT07534241Updated Nov 18, 2026

Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients

An interventional study of reishi mushroom- (Ganoderma lucidum) and Placebo in Lipid Profile and Liver Biomarkers, sponsored by University of Lahore. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Lahore · Not applicable, Interventional, and Health services research

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Study summary

This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress.

Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in

Read the detailed description

This study evaluates the therapeutic potential of (Ganoderma lucidum), combined with a probiotic-rich diet, to impose immunomodulatory and hepatoprotective effects in adults (35-65 years old) diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD). A 12-week randomized controlled trial (RCT) will be conducted, enrolling participants into three arms: a control group (starch capsules) and two intervention groups receiving either 250 mg or 500 mg of standardized Reishi extract daily. Primary outcomes include improvements in liver function markers (ALT, AST, ALP), lipid metabolism (LDL-C, HDL-C, triglycerides), and inflammatory biomarkers (CRP, IL-6). Secondary outcomes will assess gut microbiota composition (via 16S rRNA sequencing) and oxidative stress markers). Preliminary evidence suggests the Reishi-probiotic combination may significantly reduce hepatic fat accumulation (p\<0.05) and serum LPS levels while increasing beneficial gut bacteria (e.g., Bifidobacterium spp.). We anticipate dose-dependent improvements in HOMA-IR scores and NF-κB suppression, correlating with triterpenoid bioavailability. If validated, this intervention could reduce reliance on pharmacotherapies by 30-40% in early-stage MAFLD, with synergistic effects observed between Beta-glucans and probiotic strains.

02

Conditions studied

  • Lipid Profile
  • Liver Biomarkers
03

In context

Lead sponsor

University of Lahore is the lead sponsor of 237 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 35-65 years
  • between 18.5 and 30 kg/m².
  • Complete Blood Count test ranges, WBC \< 4,000-11,000 cells/µL, RBC Men \< 4.5-6.0 / Women 4.0-5.5 million/µL, : Men \< 13.5-17.5 / Women 12.0-15.5 g/dL, \< 150,000-450,000 cells/µL.
  • Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high.
  • Liver function test markers, > 56 U/L, AST>40 U/L, ALP>147 UL.
  • Inflammatory markers: CRP >3 mg/L, - IL-6 ≥3 pg/mL, TNF-α ≥8 pg/mL.
  • Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg/dL, fasting or 200 mg/dL post-meal.

Exclusion criteria

Exclusion Criteria:

  • ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment.

    • Pregnant or lactating women.
    • Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy.
    • Allergic to mushrooms.
    • Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis).
    • History of .
    • Participation in another clinical trial within the last 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
102 participants (estimated)

Study arms

  • Placebo comparator
    Conventional Group (To)

    starch capsules

    Dietary Supplement: Placebo

  • Experimental
    Experimental Group (T1)

    Each capsule contains 250 mg of Reishi mushroom dried powder, to be taken alongside a probiotic-rich diet.

    Dietary Supplement: reishi mushroom- (Ganoderma lucidum) · Dietary Supplement: Reishi mushroom dried powder

  • Experimental
    Experimental Group (T2)

    Each capsule contains 250 mg of Reishi mushroom dried powder, to be taken twice alongside a probiotic-rich diet.

    Dietary Supplement: reishi mushroom- (Ganoderma lucidum) · Dietary Supplement: Reishi mushroom dried powder

Interventions

  • Dietary supplementLingzhi mushroomStudies of Lingzhi mushroomLingzhi mushroom pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each capsule contains 250 mg of Reishi mushroom dried powder, to be taken alongside a probiotic-rich diet.

  • Dietary supplementPlacebo

    STARCH CAPCULE

  • Dietary supplementReishi mushroom dried powder

    Reishi mushroom dried powder ONCE A DAY

  • Dietary supplementReishi mushroom dried powder

    Reishi mushroom dried powder TWICE A DAY

06

What researchers measure

Primary outcomes

  1. LIPID PROFILE

    Fasting blood samples will be collected at baseline and post-intervention to measure serum levels

    Time frame: 12 WEEKS

Secondary outcomes

  1. Liver enzymes

    * Alanine Aminotransferase (ALT): Assessed using validated methods * Aspartate Aminotransferase (AST): Measured according to established protocols * Alkaline Phosphatase (ALP): Activity determined using outlined methods

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2025 → Dec 2026, primary completion Dec 2025 → Mar 2027 and completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 16, 2026
StartEst.
Dec 2, 2026was Oct 2025
Primary completionEst.
Mar 31, 2027was Dec 2025
CompletionEst.
Apr 15, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2, 2025→Dec 2, 2026
Nov 18, 2026
Primary completion
Dec 31, 2025→Mar 31, 2027
Nov 18, 2026
Study completion
Dec 15, 2026→Apr 15, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 2, 2025→Dec 2, 2026
    Primary completion Dec 31, 2025→Mar 31, 2027
    Study completion Dec 15, 2026→Apr 15, 2027
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07534241
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Dec 2, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Sana Noreen, PhD
Contact
sananoreen.rizwan@gmail.com
03018661160

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lingzhi mushroom

Start the discussion